PTC Therapeutics Q1 rev $220M (+48% YoY), DMD $170M; FY23 guidance reaffirmed

PTC THERAPEUTICS, INC.

2023-Q1 EPS reported -$1.88 revenue$220,382,000

Total revenue $220.4M vs $148.7M YoY (+48%); net product revenue $187.6M vs $129.8M.
Translarna net revenue $115.1M (+45% YoY); Emflaza $54.6M (+12% YoY); Evrysdi royalty $30.8M (+63%).
GAAP net loss $139.0M vs $126.7M; cash $286.3M at quarter-end vs $410.7M at Dec 31.
Reaffirmed FY2023 total revenue guidance $940M-$1.0B; DMD franchise $545-565M.
Four clinical readouts expected in Q2 2023, incl. registration trials for sepiapterin (PKU), vatiquinone (FA & mito disease), and PTC518 (HD) interim data.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PTC THERAPEUTICS, INC. reported the first quarter ending March 31, 2023 results: revenue $220.4 million. Guidance reaffirmed.

Period: the first quarter ending March 31, 2023
Revenue: $220.4 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

this Item 2.02. --- EX-99.1 (EX-99.1) --- PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results – First-quarter 2023 total revenue of $220 million, representing 48% year-over-year growth - – Readouts from four clinical studies expected in second quarter of 2023, three of which are registration-directed – SOUTH

View on SEC.gov

Browse all earnings releases →

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001070081-23-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.